<!DOCTYPE html>
<html lang="en" dir="ltr"><head>
  
                           
     


<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="generator" content="Hugo 0.85.0" />
<title>Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019) A multicenter, phase 2 study | Personal website of Di Shao</title>


<meta property="twitter:site" content="@apreshill">
<meta property="twitter:creator" content="@apreshill">







  
    
  
<meta name="description" content="We designed this study to assess the feasibility, safety and efficacy of neoadjuvant camrelizumab plus chemotherapy in patients with resectable ESCC.">


<meta property="og:site_name" content="Personal website of Di Shao">
<meta property="og:title" content="Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019) A multicenter, phase 2 study | Personal website of Di Shao">
<meta property="og:description" content="We designed this study to assess the feasibility, safety and efficacy of neoadjuvant camrelizumab plus chemotherapy in patients with resectable ESCC." />
<meta property="og:type" content="page" />
<meta property="og:url" content="https://dishao.netlify.app/project/nic_escc2019/" />
<meta property="og:locale" content="en">




    
        <meta property="og:image" content="https://dishao.netlify.app/project/nic_escc2019/featured.png" >
        <meta property="twitter:card" content="summary_large_image">
        <meta name="twitter:image" content="https://dishao.netlify.app/project/nic_escc2019/featured.png" >
    
    
  <meta itemprop="name" content="Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019) A multicenter, phase 2 study">
<meta itemprop="description" content="BACKGROUND Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD-1 blockade with neoadjuvant therapy.
METHODS This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. Patients (clinical stage II-IVA) received two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab-paclitaxel (260 mg/m2 in total on day 1 and day 8) and cisplatin (75 mg/m2 in total on days 1-3) of each 21-day cycle.">

<meta itemprop="wordCount" content="247"><meta itemprop="image" content="https://dishao.netlify.app/project/nic_escc2019/featured.png">
<meta itemprop="keywords" content="esophageal cancer," />
  
  <!--[if IE]><script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]-->
  <link rel="shortcut icon" href="/img/icons8-cancer-64.png" type="image/x-icon">
  <link rel="icon" href="/img/icons8-cancer-64.png" type="image/x-icon">
  
  
  <link rel="stylesheet" href="/style.main.min.c41989e55e447ba851529faee9089cf175da56ad7aa754b67d2288a69ba974e6.css" integrity="sha256-xBmJ5V5Ee6hRUp&#43;u6Qic8XXaVq16p1S2fSKIppupdOY=" media="screen">
  
  
  <script src="/panelset.min.078a92db9bd3228df502db3d9e0453c3cf3d910abe3f8deca0ad196c7071ad41.js" type="text/javascript"></script>
  
  
  <script src="/main.min.38a0323c5b0bbb611c4874ba2d8fdaba57d20cc2b0d704b30250c235ba8b6d49.js" type="text/javascript"></script>
</head>
<body>
      <div class="grid-container single">
<header class="site-header pt4 pb2 mb4 bb b--transparent ph5 headroom z-max" role="banner">
  <nav class="site-nav db dt-l w-100" role="navigation">
    <a class="site-brand db dtc-l v-mid link no-underline w-100 w-33-l tc tl-l" href="https://dishao.netlify.app" title="Home">
      <img src="/img/6745552_preview.png" class="dib db-l h2 w-auto" alt="Personal website of Di Shao">
    </a>
    <div class="site-links db dtc-l v-mid w-100 w-47-l tc tr-l mt3 mt0-l ttu tracked">
      
        
        
        
      <a class="link f6 f5-l dib pv1 ph2 " href="/about/" title="About Me">About</a>
      
        
        
        
      <a class="link f6 f5-l dib pv1 ph2 " href="/blog/" title="Blog">Blog</a>
      
        
        
        
      <a class="link f6 f5-l dib pv1 ph2 active" href="/project/" title="Project Portfolio">Projects</a>
      
        
        
        
      <a class="link f6 f5-l dib pv1 ph2 " href="/talk/" title="Talks">Talks</a>
      
        
        
        
      <a class="link f6 f5-l dib pv1 ph2 " href="/cv/" title="CV">CV</a>
      
      
    </div>
  </nav>
</header>

<main class="page-main pa4" role="main">
  <section class="page-content mw7 center">
    <article class="post-content pa0 ph4-l">
      <header class="post-header">
        <h1 class="f1 lh-solid measure-narrow mb3 fw4">Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019) A multicenter, phase 2 study</h1>
        
        
        <p class="f7 db mv0 ttu">January 1, 0001</p>

      
      <div class="ph0 pt5">
        
    
    
    
      
    
    
    
    
    
      
      
  <a class="btn-links mr2 ba dib" href="https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33976" target="_blank" rel="noopener"><i class="far fa-newspaper fa-lg fa-fw mr2"></i>Full article</a>


      </div>
      

      </header>
      <section class="post-body pt5 pb4">
        <p><img src="fig0.png" alt=""></p>
<p><strong>BACKGROUND</strong>
Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD-1 blockade with neoadjuvant therapy.</p>
<p><strong>METHODS</strong>
This phase 2 study aimed to assess neoadjuvant camrelizumab plus chemotherapy in this population. Patients (clinical stage II-IVA) received two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab-paclitaxel (260 mg/m2 in total on day 1 and day 8) and cisplatin (75 mg/m2 in total on days 1-3) of each 21-day cycle. Surgery was performed approximately 6 weeks after completion of NIC. Primary endpoint was complete pathologic response (CPR) rate in primary tumor. Secondary endpoints were objective response rate (ORR) per RECIST v1.1, 2-year progression-free survival (PFS) rate after surgery, PFS, overall survival (OS) and safety during NIC and perioperative period.</p>
<p><strong>RESULTS</strong>
Between 17 January 2020 and 8 December 2020, 56 patients were enrolled, and 51 received esophagectomy. Data cutoff date was 25 August 2021. The CPR rate was 35.3% (95% CI, 21.7%-48.9%). NIC had an ORR of 66.7% (95% CI, 40.0%-70.4%) and treatment-related adverse events (TRAEs) of low severity (grade 1-2, 75.0%; grade 3, 10.7%; grade 4-5, no). No perioperative mortality occurred. Three (5.9%) patients had tumor recurrence and one (2.0%) patient died. The 2-year PFS rate, median PFS and median OS had not been reached yet.</p>
<p><strong>CONCLUSIONS</strong>
Camrelizumab plus neoadjuvant chemotherapy in resectable ESCC demonstrates promising efficacy with acceptable toxicity, providing a feasible and effective option. Study is ongoing for long-term survival analyses.</p>
<p><img src="fig1.png" alt=""></p>

        
        <details closed class="f6 fw7 input-reset">
  <dl class="f6 lh-copy">
    <dt class="fw7">Posted on:</dt>
    <dd class="fw5 ml0">January 1, 0001</dd>
  </dl>
  <dl class="f6 lh-copy">
    <dt class="fw7">Length:</dt>
    <dd class="fw5 ml0">2 minute read, 247 words</dd>
  </dl>
  
  <dl class="f6 lh-copy">
    <dt class="fw7">Categories:</dt>
    <dd class="fw5 ml0"> <a href="https://dishao.netlify.app/categories/ec">EC,</a>  <a href="https://dishao.netlify.app/categories/phase-ii-clinical-trial">Phase II clinical trial,</a>  <a href="https://dishao.netlify.app/categories/camrelizumab">Camrelizumab</a> </dd>
  </dl>
  
  
  
  <dl class="f6 lh-copy">
    <dt class="fw7">Tags:</dt>
    <dd class="fw5 ml0"> <a href="https://dishao.netlify.app/tags/esophageal-cancer">esophageal cancer</a> </dd>
  </dl>
  
  <dl class="f6 lh-copy">
    <dt class="fw7">See Also:</dt>
    
  </dl>
</details>

      </section>
      <footer class="post-footer">
        <div class="post-pagination dt w-100 mt4 mb2">
  
  
    <a class="prev dtc pr2 tl v-top fw6"
    href="https://dishao.netlify.app/project/hrd/">&larr; Homologous recombination deficiency status predicts response to platinum‑based chemotherapy in Chinese patients with high‑grade serous ovarian carcinoma</a>
  
  
  
</div>

      </footer>
    </article>
    
  </section>
</main>
<footer class="site-footer pv4 bt b--transparent ph5" role="contentinfo">
  <nav class="db dt-l w-100">
    <p class="site-copyright f7 db dtc-l v-mid w-100 w-33-l tc tl-l pv2 pv0-l mv0 lh-copy">
      &copy; 2023 Di Shao, Shenzhen
      <span class="middot-divider"></span>
      Made with <span xmlns:dct="http://purl.org/dc/terms/" property="dct:title"><a xmlns:dct="http://purl.org/dc/terms/" href="https://github.com/hugo-apero/" rel="dct:source">Hugo Apéro</a></span>.
      <br />
      
Based on <span xmlns:dct="http://purl.org/dc/terms/" property="dct:title"><a xmlns:dct="http://purl.org/dc/terms/" href="https://github.com/formspree/blogophonic-hugo" rel="dct:source">Blogophonic</a></span> by <a xmlns:cc="http://creativecommons.org/ns#" href="https://formspree.io" property="cc:attributionName" rel="cc:attributionURL">Formspree</a>.
    </p>
    
    <div class="site-social-links db dtc-l v-mid w-100 w-33-l tc pv2 pv0-l mv0">
      <div class="social-icon-links" aria-hidden="true">
  
  
    
    
    
      
    
    
    
    
    
      
    
    <a class="link dib h1 w1 ml0 mr2 f6 o-90 glow" href="https://www.jianguoyun.com/p/DX1SvlkQ98bmBRjO6pcE" title="weixin" target="_blank" rel="noopener">
      <i class="fab fa-weixin fa-lg fa-fw"></i>
    </a>
  
    
    
    
      
    
    
    
    
    
      
    
    <a class="link dib h1 w1 ml0 mr2 f6 o-90 glow" href="https://www.linkedin.com/in/%E8%BF%AA-%E9%82%B5-0a68259a/" title="linkedin" target="_blank" rel="noopener">
      <i class="fab fa-linkedin fa-lg fa-fw"></i>
    </a>
  
    
    
    
    
    
    
    
      
    
    <a class="link dib h1 w1 ml0 mr2 f6 o-90 glow" href="https://orcid.org/0000-0002-1485-2074" title="orcid" target="_blank" rel="noopener">
      <i class="ai ai-orcid fa-lg fa-fw"></i>
    </a>
  
    
    
    
      
    
    
    
    
    
      
    
    <a class="link dib h1 w1 ml0 mr2 f6 o-90 glow" href="https://github.com/Di-Shao" title="github" target="_blank" rel="noopener">
      <i class="fab fa-github fa-lg fa-fw"></i>
    </a>
  
    
    
    
      
    
    
    
    
    
      
    
    <a class="link dib h1 w1 ml0 mr2 f6 o-90 glow" href="/blog/index.xml" title="rss" >
      <i class="fas fa-rss fa-lg fa-fw"></i>
    </a>
  
</div>

    </div>
    
    <div class="site-links f6 db dtc-l v-mid w-100 w-67-l tc tr-l pv2 pv0-l mv0">
      
      <a class="dib pv1 ph2 link" href="/license/" title="License">License</a>
      
      <a class="dib pv1 ph2 link" href="/contact/" title="Contact form">Contact</a>
      
    </div>
  </nav>
</footer>

      </div>
    </body>
</html>
